Biotech Archives - Page 66 of 795

2 minute read

ClearPoint Neuro Congratulates Its Partner AviadoBio On First Patient Treated In Its ASPIRE-FTD Clinical Trial Evaluating AVB-101 For Frontotemporal Dementia With GRN Mutations

April 16, 4:23 PM

ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today congratulates its partner AviadoBio on treating its

CLPT

3 minute read

Omnicell Announces XT Amplify, A Multi-Year Innovation Program That Is Intended To Maximize Value For Hospitals, Health Systems, And Post-Acute Care Facilities That Have Invested In Omnicell’s XT Automated Dispensing System

By Benzinga Newsdesk

April 16, 4:14 PM

Multi-year Innovation Program Designed to Maximize Value and Outcomes for XT Automated Dispensing SystemOmnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leader in transforming the pharmacy care delivery

OMCL

3 minute read

InMed Pharmaceuticals Provides Update On INM-089 In The Treatment Of Dry Age-Related Macular Degeneration; Small Molecule Drug Acting As A Preferential Signaling Ligand For CB1/CB2

By Benzinga Newsdesk

April 16, 2:42 PM

InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration ● Small molecule drug acting as a preferential signaling ligand for CB1/CB2 ● Delivers improved retinal pigment epithelium integrity, neuroprotection and photoreceptor improvement in in vivo preclinical disease model

INM

2 minute read

Avalo Therapeutics’ Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades

By Vandana Singh

April 16, 2:25 PM

Unlock the potential of Avalo Therapeutics with AVTX-009, a promising drug for hidradenitis suppurativa. Oppenheimer upgrades to Outperform, foreseeing Phase 2 progress and market distinction.

ABBV

2 minute read

Cullinan Shifts Focus From Oncology To Autoimmune Disorders, Raises $280M Via Equity

By Vandana Singh

April 16, 1:32 PM

Cullinan shifts focus to autoimmune diseases with CLN-978, targeting systemic lupus erythematosus. Initial trial results show potential for treatment with a differentiated safety profile.

CGEM

2 minute read

Intra-Cellular Stock Rallies On Successful Late-Stage Depression Treatment Study

By Vandana Singh

April 16, 12:13 PM

Unlock new hope for major depressive disorder with Lumateperone 42 mg. Results from Intra-Cellular's Study 501, show significant symptom relief as adjunctive therapy to antidepressants.

ITCI

2 minute read

IGC Pharma Says Cannabinoid-Based Drug Candidate Provides Fast Relief With Fewer Side Effects For Alzheimer’s-Associated Agitation

By Vandana Singh

April 16, 11:47 AM

IGC Pharma shares encouraging interim data from Phase 2 trial of IGC-AD1 for Alzheimer's agitation. Results suggest significant reduction in agitation with minimal side effects compared to placebo.

IGC

2 minute read

Johnson & Johnson Q1 Earnings Tops Wall Street Estimates On Strong Medical Devices Sales, Boosts Annual Outlook

By Vandana Singh

April 16, 9:29 AM

Johnson & Johnson reports Q1 results: adjusted EPS $2.71 (up 12.4% Y/Y), sales $21.38B (up 2.3% Y/Y). Explore pharma giant's robust performance, including strong growth in Innovative Medicine and medical devices sales.

JNJ

2 minute read

Petros Pharmaceuticals Receives Response From FDA Following Recent Demonstration Of Technology Component In Pursuit Of OTC Status For STENDRA

By Benzinga Newsdesk

April 16, 9:18 AM

Petros Pharmaceuticals, Inc. ("Petros," or the "Company") (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug development programs, announces it has received

PTPI

2 minute read

Lexaria Receives Ethics Review Board Approval To Begin New GLP-1 Study, Investigating GLP-1 Drugs And DehydraTECH

By Benzinga Newsdesk

April 16, 9:17 AM

Human Pilot Study #2 (GLP-1-H24-2) ApprovedKELOWNA, BC / ACCESSWIRE / April 16, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms,

LEXX